Pharmacokinetics and pharmacodynamics of injectable testosterone undecanoate in castrated cynomolgus monkeys (Macaca fascicularis) are independent of different oil vehicles
- PMID: 16053495
- DOI: 10.1111/j.1600-0684.2005.00115.x
Pharmacokinetics and pharmacodynamics of injectable testosterone undecanoate in castrated cynomolgus monkeys (Macaca fascicularis) are independent of different oil vehicles
Abstract
Testosterone undecanoate (TU) dissolved in soybean oil was developed in China to improve the pharmacokinetics of this testosterone ester in comparison with TU in castor or tea seed oil. As a pre-clinical primate model, three groups of five castrated cynomolgus macaques received either a single intramuscular injection of 10 mg/kg body weight TU in soybean oil, in tea seed oil, or in castor oil (equals 6.3 mg pure T/kg body weight for all preparations). Testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone as well as prostate volume, body weight and ejaculate weight were evaluated. After injection supraphysiological testosterone levels were induced. There were no significant differences in the pharmacokinetics of the three TU preparations for testosterone and estradiol. The gonadotropin levels showed a high individual variation. Prostate volumes increased equally in all groups after administration and declined to castrate level afterwards. The results suggest that TU in soybean oil produces similar effects as TU in the other vehicles. This study in non-human primates provides no objection to testing of this new preparation in humans.
Similar articles
-
Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.J Androl. 2002 May-Jun;23(3):419-25. J Androl. 2002. PMID: 12002444 Clinical Trial.
-
A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.J Androl. 1998 Nov-Dec;19(6):761-8. J Androl. 1998. PMID: 9876028
-
Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate.Eur J Endocrinol. 1995 Apr;132(4):514-9. doi: 10.1530/eje.0.1320514. Eur J Endocrinol. 1995. PMID: 7711892
-
More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.Asian J Androl. 2007 May;9(3):291-7. doi: 10.1111/j.1745-7262.2007.00275.x. Asian J Androl. 2007. PMID: 17486268 Review.
-
Testosterone treatment comes of age: new options for hypogonadal men.Clin Endocrinol (Oxf). 2006 Sep;65(3):275-81. doi: 10.1111/j.1365-2265.2006.02618.x. Clin Endocrinol (Oxf). 2006. PMID: 16918944 Review.
Cited by
-
The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic Cancers.PLoS One. 2015 Dec 14;10(12):e0144890. doi: 10.1371/journal.pone.0144890. eCollection 2015. PLoS One. 2015. PMID: 26660672 Free PMC article.
-
Critical factors influencing the in vivo performance of long-acting lipophilic solutions--impact on in vitro release method design.AAPS J. 2009 Dec;11(4):762-70. doi: 10.1208/s12248-009-9153-9. Epub 2009 Nov 6. AAPS J. 2009. PMID: 19894123 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
